Gene Therapy Market 2025: Breakthrough Innovations, Clinical Advancements, and Global Forecast to 2031

Los Angeles, United State- QY Research announced the publication of a new research report, It sheds light on the global Gene Therapy market. The research report is collated using primary and secondary research methodologies to provide the users with a precise analysis of the market dynamics. Analysts have used SWOT analysis and Porter's five forces analysis for providing the readers with a detailed understanding of the influence of the various market dynamics. It answers questions pertaining to the present market size and its estimated valuation at the end of the forecast period.

The global market for Gene Therapy was estimated to be worth US$ 11480 million in 2024 and is forecast to a readjusted size of US$ 61870 million by 2031 with a CAGR of 27.6% during the forecast period 2025-2031.

Get PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) https://www.qyresearch.in/request-sample/medical-care-gene-therapy-global-market-share-and-ranking-overall-sales-and-demand-forecast-2025-2031

The Gene Therapy market is driven by the growing demand for innovative treatments for rare genetic disorders, cancers, and chronic diseases that lack effective conventional therapies. Advancements in gene editing technologies such as CRISPR/Cas9, improved viral and non-viral delivery vectors, and increasing knowledge of the human genome have made gene therapy a promising option in precision medicine. Regulatory agencies are also offering accelerated approval pathways for breakthrough gene therapies, encouraging investment and speeding up clinical development. In addition, rising public and private funding, along with successful commercialization of landmark therapies like Zolgensma and Luxturna, are fueling confidence and expansion in this market.

Despite its potential, the Gene Therapy market faces several critical challenges, including high development and treatment costs, complex manufacturing processes, and safety concerns. Producing gene therapies requires highly specialized facilities and stringent quality control, leading to limited scalability and high prices, which can exceed millions of dollars per patient. Furthermore, long-term safety data are still lacking, with concerns over immune responses, off-target effects, and durability of treatment outcomes. Regulatory, ethical, and reimbursement hurdles also pose significant barriers to broader adoption. Addressing these challenges is essential to ensure accessibility, affordability, and the long-term success of gene therapy as a mainstream medical solution.

Global Gene Therapy key players include Biogen, Novartis, Gilead Sciences, etc. Global top three manufacturers hold a share about 75%. North America is the largest market, with a share about 60%, followed by Europe and Asia-Pacific, both have a share about 35 percent. In terms of product, Non-viral Gene Therapy is the largest segment, with a share about 55%. And in terms of application, the largest application is Neurological Diseases, followed by Cancer.

Details of Gene Therapy Market Segmentation: -

Segment by Key Manufacturers:

Biogen
Novartis
Gilead Sciences
Sarepta Therapeutics
Alnylam Pharmaceuticals
Amgen
Roche
Akcea Therapeutics
bluebird bio
Sunway Biotech
SIBIONO
AnGes
Orchard Therapeutics
Human Stem Cells Institute
CSL Behring
BioMarin Pharmaceutical

Segment by Type

Viral Gene Therapy
Non-Viral Gene Therapy

Segment by Application

Neurological Diseases
Cancer
Other

In the successive chapters, the reports study the segments present in the global Gene Therapy market. The market is segmented on the basis of application, type of product, service, and end users. Each of these segments have a dedicated chapter, which highlights the reasons for its progress and decline. Analysts have justified the reasons for the progress of each of these segments. The approach of end users, affordability, durability, and impact on business have been studied in great detail by analysts to understand the evolution of segments in the global Gene Therapy market.

What to expect in our report?

(1) A complete section of the Gene Therapy market report is dedicated for market dynamics, which include influence factors, market drivers, challenges, opportunities, and trends.

(2) Another broad section of the research study is reserved for regional analysis of the global Gene Therapy market where important regions and countries are assessed for their growth potential, consumption, market share, and other vital factors indicating their market growth.

(3) Players can use the competitive analysis provided in the report to build new strategies or fine-tune their existing ones to rise above market challenges and increase their share of the global Gene Therapy market.

(4) The report also discusses competitive situation and trends and sheds light on company expansions and merger and acquisition taking place in the global Gene Therapy market. Moreover, it brings to light the market concentration rate and market shares of top three and five players.

(5) Readers are provided with findings and conclusion of the research study provided in the Gene Therapy Market report.

Unlock Exclusive Market Insights - Customize Your Research Report Now! https://www.qyresearch.in/pre-order-inquiry/medical-care-gene-therapy-global-market-share-and-ranking-overall-sales-and-demand-forecast-2025-2031

Table of Content

1 Market Overview
1.1 Gene Therapy Product Introduction
1.2 Global Gene Therapy Market Size Forecast (2020-2031)
1.3 Gene Therapy Market Trends & Drivers
1.3.1 Gene Therapy Industry Trends
1.3.2 Gene Therapy Market Drivers & Opportunity
1.3.3 Gene Therapy Market Challenges
1.3.4 Gene Therapy Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered

2 Competitive Analysis by Company
2.1 Global Gene Therapy Players Revenue Ranking (2024)
2.2 Global Gene Therapy Revenue by Company (2020-2025)
2.3 Key Companies Gene Therapy Manufacturing Base Distribution and Headquarters
2.4 Key Companies Gene Therapy Product Offered
2.5 Key Companies Time to Begin Mass Production of Gene Therapy
2.6 Gene Therapy Market Competitive Analysis
2.6.1 Gene Therapy Market Concentration Rate (2020-2025)
2.6.2 Global 5 and 10 Largest Companies by Gene Therapy Revenue in 2024
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gene Therapy as of 2024)
2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Viral Gene Therapy
3.1.2 Non-Viral Gene Therapy
3.2 Global Gene Therapy Sales Value by Type
3.2.1 Global Gene Therapy Sales Value by Type (2020 VS 2024 VS 2031)
3.2.2 Global Gene Therapy Sales Value, by Type (2020-2031)
3.2.3 Global Gene Therapy Sales Value, by Type (%) (2020-2031)

4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Neurological Diseases
4.1.2 Cancer
4.1.3 Other
4.2 Global Gene Therapy Sales Value by Application
4.2.1 Global Gene Therapy Sales Value by Application (2020 VS 2024 VS 2031)
4.2.2 Global Gene Therapy Sales Value, by Application (2020-2031)
4.2.3 Global Gene Therapy Sales Value, by Application (%) (2020-2031)

5 Segmentation by Region
5.1 Global Gene Therapy Sales Value by Region
5.1.1 Global Gene Therapy Sales Value by Region: 2020 VS 2024 VS 2031
5.1.2 Global Gene Therapy Sales Value by Region (2020-2025)
5.1.3 Global Gene Therapy Sales Value by Region (2026-2031)
5.1.4 Global Gene Therapy Sales Value by Region (%), (2020-2031)
5.2 North America
5.2.1 North America Gene Therapy Sales Value, 2020-2031
5.2.2 North America Gene Therapy Sales Value by Country (%), 2024 VS 2031
5.3 Europe
5.3.1 Europe Gene Therapy Sales Value, 2020-2031
5.3.2 Europe Gene Therapy Sales Value by Country (%), 2024 VS 2031
5.4 Asia Pacific
5.4.1 Asia Pacific Gene Therapy Sales Value, 2020-2031
5.4.2 Asia Pacific Gene Therapy Sales Value by Region (%), 2024 VS 2031
5.5 South America
5.5.1 South America Gene Therapy Sales Value, 2020-2031
5.5.2 South America Gene Therapy Sales Value by Country (%), 2024 VS 2031
5.6 Middle East & Africa
5.6.1 Middle East & Africa Gene Therapy Sales Value, 2020-2031
5.6.2 Middle East & Africa Gene Therapy Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Gene Therapy Sales Value Growth Trends, 2020 VS 2024 VS 2031
6.2 Key Countries/Regions Gene Therapy Sales Value, 2020-2031
6.3 United States
6.3.1 United States Gene Therapy Sales Value, 2020-2031
6.3.2 United States Gene Therapy Sales Value by Type (%), 2024 VS 2031
6.3.3 United States Gene Therapy Sales Value by Application, 2024 VS 2031
6.4 Europe
6.4.1 Europe Gene Therapy Sales Value, 2020-2031
6.4.2 Europe Gene Therapy Sales Value by Type (%), 2024 VS 2031
6.4.3 Europe Gene Therapy Sales Value by Application, 2024 VS 2031
6.5 China
6.5.1 China Gene Therapy Sales Value, 2020-2031
6.5.2 China Gene Therapy Sales Value by Type (%), 2024 VS 2031
6.5.3 China Gene Therapy Sales Value by Application, 2024 VS 2031
6.6 Japan
6.6.1 Japan Gene Therapy Sales Value, 2020-2031
6.6.2 Japan Gene Therapy Sales Value by Type (%), 2024 VS 2031
6.6.3 Japan Gene Therapy Sales Value by Application, 2024 VS 2031
6.7 South Korea
6.7.1 South Korea Gene Therapy Sales Value, 2020-2031
6.7.2 South Korea Gene Therapy Sales Value by Type (%), 2024 VS 2031
6.7.3 South Korea Gene Therapy Sales Value by Application, 2024 VS 2031
6.8 Southeast Asia
6.8.1 Southeast Asia Gene Therapy Sales Value, 2020-2031
6.8.2 Southeast Asia Gene Therapy Sales Value by Type (%), 2024 VS 2031
6.8.3 Southeast Asia Gene Therapy Sales Value by Application, 2024 VS 2031
6.9 India
6.9.1 India Gene Therapy Sales Value, 2020-2031
6.9.2 India Gene Therapy Sales Value by Type (%), 2024 VS 2031
6.9.3 India Gene Therapy Sales Value by Application, 2024 VS 2031

7 Company Profiles
7.1 Biogen
7.1.1 Biogen Profile
7.1.2 Biogen Main Business
7.1.3 Biogen Gene Therapy Products, Services and Solutions
7.1.4 Biogen Gene Therapy Revenue (US$ Million) & (2020-2025)
7.1.5 Biogen Recent Developments
7.2 Novartis
7.2.1 Novartis Profile
7.2.2 Novartis Main Business
7.2.3 Novartis Gene Therapy Products, Services and Solutions
7.2.4 Novartis Gene Therapy Revenue (US$ Million) & (2020-2025)
7.2.5 Novartis Recent Developments
7.3 Gilead Sciences
7.3.1 Gilead Sciences Profile
7.3.2 Gilead Sciences Main Business
7.3.3 Gilead Sciences Gene Therapy Products, Services and Solutions
7.3.4 Gilead Sciences Gene Therapy Revenue (US$ Million) & (2020-2025)
7.3.5 Gilead Sciences Recent Developments
7.4 Sarepta Therapeutics
7.4.1 Sarepta Therapeutics Profile
7.4.2 Sarepta Therapeutics Main Business
7.4.3 Sarepta Therapeutics Gene Therapy Products, Services and Solutions
7.4.4 Sarepta Therapeutics Gene Therapy Revenue (US$ Million) & (2020-2025)
7.4.5 Sarepta Therapeutics Recent Developments
7.5 Alnylam Pharmaceuticals
7.5.1 Alnylam Pharmaceuticals Profile
7.5.2 Alnylam Pharmaceuticals Main Business
7.5.3 Alnylam Pharmaceuticals Gene Therapy Products, Services and Solutions
7.5.4 Alnylam Pharmaceuticals Gene Therapy Revenue (US$ Million) & (2020-2025)
7.5.5 Alnylam Pharmaceuticals Recent Developments
7.6 Amgen
7.6.1 Amgen Profile
7.6.2 Amgen Main Business
7.6.3 Amgen Gene Therapy Products, Services and Solutions
7.6.4 Amgen Gene Therapy Revenue (US$ Million) & (2020-2025)
7.6.5 Amgen Recent Developments
7.7 Roche
7.7.1 Roche Profile
7.7.2 Roche Main Business
7.7.3 Roche Gene Therapy Products, Services and Solutions
7.7.4 Roche Gene Therapy Revenue (US$ Million) & (2020-2025)
7.7.5 Roche Recent Developments
7.8 Akcea Therapeutics
7.8.1 Akcea Therapeutics Profile
7.8.2 Akcea Therapeutics Main Business
7.8.3 Akcea Therapeutics Gene Therapy Products, Services and Solutions
7.8.4 Akcea Therapeutics Gene Therapy Revenue (US$ Million) & (2020-2025)
7.8.5 Akcea Therapeutics Recent Developments
7.9 bluebird bio
7.9.1 bluebird bio Profile
7.9.2 bluebird bio Main Business
7.9.3 bluebird bio Gene Therapy Products, Services and Solutions
7.9.4 bluebird bio Gene Therapy Revenue (US$ Million) & (2020-2025)
7.9.5 bluebird bio Recent Developments
7.10 Sunway Biotech
7.10.1 Sunway Biotech Profile
7.10.2 Sunway Biotech Main Business
7.10.3 Sunway Biotech Gene Therapy Products, Services and Solutions
7.10.4 Sunway Biotech Gene Therapy Revenue (US$ Million) & (2020-2025)
7.10.5 Sunway Biotech Recent Developments
7.11 SIBIONO
7.11.1 SIBIONO Profile
7.11.2 SIBIONO Main Business
7.11.3 SIBIONO Gene Therapy Products, Services and Solutions
7.11.4 SIBIONO Gene Therapy Revenue (US$ Million) & (2020-2025)
7.11.5 SIBIONO Recent Developments
7.12 AnGes
7.12.1 AnGes Profile
7.12.2 AnGes Main Business
7.12.3 AnGes Gene Therapy Products, Services and Solutions
7.12.4 AnGes Gene Therapy Revenue (US$ Million) & (2020-2025)
7.12.5 AnGes Recent Developments
7.13 Orchard Therapeutics
7.13.1 Orchard Therapeutics Profile
7.13.2 Orchard Therapeutics Main Business
7.13.3 Orchard Therapeutics Gene Therapy Products, Services and Solutions
7.13.4 Orchard Therapeutics Gene Therapy Revenue (US$ Million) & (2020-2025)
7.13.5 Orchard Therapeutics Recent Developments
7.14 Human Stem Cells Institute
7.14.1 Human Stem Cells Institute Profile
7.14.2 Human Stem Cells Institute Main Business
7.14.3 Human Stem Cells Institute Gene Therapy Products, Services and Solutions
7.14.4 Human Stem Cells Institute Gene Therapy Revenue (US$ Million) & (2020-2025)
7.14.5 Human Stem Cells Institute Recent Developments
7.15 CSL Behring
7.15.1 CSL Behring Profile
7.15.2 CSL Behring Main Business
7.15.3 CSL Behring Gene Therapy Products, Services and Solutions
7.15.4 CSL Behring Gene Therapy Revenue (US$ Million) & (2020-2025)
7.15.5 CSL Behring Recent Developments
7.16 BioMarin Pharmaceutical
7.16.1 BioMarin Pharmaceutical Profile
7.16.2 BioMarin Pharmaceutical Main Business
7.16.3 BioMarin Pharmaceutical Gene Therapy Products, Services and Solutions
7.16.4 BioMarin Pharmaceutical Gene Therapy Revenue (US$ Million) & (2020-2025)
7.16.5 BioMarin Pharmaceutical Recent Developments

8 Industry Chain Analysis
8.1 Gene Therapy Industrial Chain
8.2 Gene Therapy Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Gene Therapy Sales Model
8.5.2 Sales Channel
8.5.3 Gene Therapy Distributors

9 Research Findings and Conclusion

10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer

About US:

QYResearch is a leading global market research and consulting company established in 2007. With over 17 years' experience and professional research team in various cities over the world QY Research focuses on management consulting, database and seminar services, IPO consulting, industry chain research and customized research to help our clients in providing non-linear revenue model and make them successful. We are globally recognized for our expansive portfolio of services, good corporate citizenship, and our strong commitment to sustainability.

Contact US

QY RESEARCH, INC.
17890 CASTLETON STREET
SUITE 369, CITY OF INDUSTRY
CA - 91748, UNITED STATES OF AMERICA
Web - https://www.qyresearch.in
Tel: +91-8149736330
Email- ankit@qyresearch.com

This release was published on openPR.